Melbourne, June 25, 2008 AEST (ABN Newswire) - According to the June edition of Bioshares, Mesoblast Limited (ASX:MSB)(USOTC:MBLTY)(PINK:MEOBF) has made exceptionally good progress with its adult stem cell therapy in several applications.
"The company has a well-constructed business plan that is positioning the company to deliver on multiple licensing opportunities.
"It has delivered positive proof of concept of the use of allogeneic adult stem cells…commercial applications will all involve allogeneic cells, with Phase 2 trials underway with the allogeneic cells, which brings it obvious and less obvious benefits.
"Mesoblast is capitalised at $125 million with $16 million in cash at the end of March," added Bioshares.
For a link to the Full Report:
http://mesoblast.com/investor/expert_analysis8.pdf
Contact
Julie Meldrum
Corporate Communications Director
Mesoblast Limited
T: + 61-3-9639-6036
M: +61-419-228-128
E: julie.meldrum@mesoblast.com
W: www.mesoblast.com
| ||
|
